share_log

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Iovance Biotherapeutics根據納斯達克上市規則5635 (c) (4) 報告了激勵補助金
Iovance Biotherapeutics ·  05/17 12:00

SAN CARLOS, Calif., May 17, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the "Company"), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer, today announced that on May 16, 2024 (the "Date of Grant"), the Company approved the grant of inducement stock options covering an aggregate of 153,930 shares of Iovance's common stock to thirty new, non-executive employees.

加利福尼亞州聖卡洛斯,2024年5月17日(GLOBE NEWSWIRE)——專注於爲癌症患者創新、開發和提供新型多克隆腫瘤浸潤淋巴細胞(“TIL”)療法的生物技術公司Iovance Biotherapeutics, Inc.(納斯達克股票代碼:IOVA)(“IOVA” 或 “公司”)今天宣佈,2024年5月16日(“日期”)Grant”)中,公司批准向三十名新的非執行員工授予激勵性股票期權,涵蓋Iovance共計153,930股普通股。

The awards were granted under Iovance's 2021 Inducement Plan, which was adopted on September 22, 2021 and amended on January 12, 2022, March 13, 2023, and February 26, 2024 and provides for the granting of equity awards to new employees of Iovance by the Company's compensation committee in accordance with Nasdaq Listing Rule 5635(c)(4). Each of the stock options granted as referenced in this press release has an exercise price of $10.43, the closing price of Iovance's common stock on the Date of Grant. Each stock option vests over a three-year period, with one-third of the shares vesting on the first anniversary of the employee's start date (the "First Vesting Date"), and the remaining shares vesting in eight quarterly installments over the next two years, commencing with the first quarter following the First Vesting Date, subject to continued employment with the Company through the applicable vesting dates.

這些獎勵是根據Iovance的2021年激勵計劃授予的,該計劃於2021年9月22日通過,並於2022年1月12日、2023年3月13日和2024年2月26日進行了修訂,規定公司薪酬委員會根據納斯達克上市規則5635(c)(4)向Iovance的新員工發放股權獎勵。本新聞稿中提及的每份授予的股票期權的行使價爲10.43美元,即授予之日Iovance普通股的收盤價。每個股票期權的歸屬期爲三年,其中三分之一的股份在員工入職一週年之際歸屬(“首次歸屬日期”),其餘股份將在未來兩年內分八個季度分期歸屬,從第一個歸屬日之後的第一季度開始,但須在適用的歸屬日期之前繼續在公司工作。

About Iovance Biotherapeutics, Inc.

關於 Iovance Biotherapeutics, Inc

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte ("TIL") therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells in each patient. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. Iovance's Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer. For more information, please visit www.iovance.com.

Iovance 生物療法, Inc. 的目標是成爲爲癌症患者創新、開發和提供腫瘤浸潤淋巴細胞(“TIL”)療法的全球領導者。我們正在開創一種變革性的癌症治療方法,利用人體免疫系統識別和摧毀每位患者體內不同的癌細胞的能力。Iovance TIL平台已經展示了針對多種實體瘤的令人鼓舞的臨床數據。Iovance的Amtagvi是美國食品藥品管理局批准的第一種用於實體瘤適應症的T細胞療法。我們致力於細胞療法的持續創新,包括基因編輯的細胞療法,這可能會延長和改善癌症患者的壽命。欲了解更多信息,請訪問 www.iovance.com

Amtagvi and its accompanying design marks, Proleukin, Iovance, and IovanceCares are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners.

Amtagvi及其附帶的設計商標Proleukin、Iovance和iovanceCares是Iovance Biotherapeutics, Inc.或其子公司的商標和註冊商標。所有其他商標和註冊商標均爲其各自所有者的財產。

Forward-Looking Statements

前瞻性陳述

Certain matters discussed in this press release are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potential," "continue," "estimates," "anticipates," "expects," "plans," "intends," "forecast," "guidance," "outlook," "may," "could," "might," "will," "should," or other words that convey uncertainty of future events or outcomes and are intended to identify forward-looking statements. Forward-looking statements are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments, and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events, or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and other factors, many of which are outside of our control, that may cause actual results, levels of activity, performance, achievements, and developments to be materially different from those expressed in or implied by these forward-looking statements. Important factors that could cause actual results, developments, and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in our filings with the U.S. Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, and include, but are not limited to, the following substantial known and unknown risks and uncertainties inherent in our business: the risks related to our ability to successfully commercialize our products, including Amtagvi, for which we have obtained U.S. Food and Drug Administration ("FDA") approval, and Proleukin, for which we have obtained FDA and European Medicines Agency ("EMA") approval; the risk that the EMA or other ex-U.S. regulatory authorities may not approve or may delay approval for our marketing authorization application submission for lifileucel in metastatic melanoma; the acceptance by the market of our products, including Amtagvi and Proleukin, and their potential pricing and/or reimbursement by payors, if approved (in the case of our product candidates), in the U.S. and other international markets and whether such acceptance is sufficient to support continued commercialization or development of our products, including Amtagvi and Proleukin, or product candidates, respectively; the risk whether the number of patients treated and/or ATCs is an appropriate measure of commercial success and/or recognized revenue; future competitive or other market factors may adversely affect the commercial potential for Amtagvi or Proleukin; the risk regarding our ability or inability to manufacture our therapies using third party manufacturers or at our own facility, including our ability to increase manufacturing capacity at such third party manufacturers and our own facility, may adversely affect our commercial launch; the results of clinical trials with collaborators using different manufacturing processes may not be reflected in our sponsored trials; the risk regarding the successful integration of the recent Proleukin acquisition; the risk that the successful development or commercialization of our products, including Amtagvi and Proleukin, may not generate sufficient revenue from product sales, and we may not become profitable in the near term, or at all; the risks related to the timing of and our ability to successfully develop, submit, obtain, or maintain FDA, EMA, or other regulatory authority approval of, or other action with respect to, our product candidates; whether clinical trial results from our pivotal studies and cohorts, and meetings with the FDA, EMA, or other regulatory authorities may support registrational studies and subsequent approvals by the FDA, EMA, or other regulatory authorities, including the risk that the planned single arm Phase 2 IOV-LUN-202 trial may not support registration; preliminary and interim clinical results, which may include efficacy and safety results from ongoing clinical trials or cohorts may not be reflected in the final analyses of our ongoing clinical trials or subgroups within these trials or in other prior trials or cohorts; the risk that enrollment may need to be adjusted for our trials and cohorts within those trials based on FDA and other regulatory agency input; the risk that the changing landscape of care for cervical cancer patients may impact our clinical trials in this indication; the risk that we may be required to conduct additional clinical trials or modify ongoing or future clinical trials based on feedback from the FDA, EMA, or other regulatory authorities; the risk that our interpretation of the results of our clinical trials or communications with the FDA, EMA, or other regulatory authorities may differ from the interpretation of such results or communications by such regulatory authorities (including from our prior meetings with the FDA regarding our non-small cell lung cancer clinical trials); the risk that clinical data from ongoing clinical trials of Amtagvi will not continue or be repeated in ongoing or planned clinical trials or may not support regulatory approval or renewal of authorization; the risk that unanticipated expenses may decrease our estimated cash balances and forecasts and increase our estimated capital requirements; the effects of the COVID-19 pandemic; and other factors, including general economic conditions and regulatory developments, not within our control.

本新聞稿中討論的某些事項是1995年《私人證券訴訟改革法》(“PSLRA”)所指的Iovance Biotherapeutics, Inc.(以下簡稱 “公司”、“我們” 或 “我們的”)的 “前瞻性陳述”。在不限制前述內容的情況下,在某些情況下,我們可以使用諸如 “預測”、“相信”、“潛在”、“繼續”、“估計”、“預期”、“計劃”、“打算”、“預測”、“指導”、“展望”、“可能”、“可能”、“將”、“應該” 等術語或其他表達未來事件不確定性的詞語或結果,旨在確定前瞻性陳述。前瞻性陳述基於管理層的經驗和對歷史趨勢、當前狀況、預期未來發展以及其他被認爲合適的因素的看法所做的假設和評估。本新聞稿中的前瞻性陳述自本新聞稿發佈之日起作出,我們沒有義務更新或修改任何此類陳述,無論是由於新信息、未來事件還是其他原因。前瞻性陳述不能保證未來的表現,並受風險、不確定性和其他因素的影響,其中許多因素是我們無法控制的,這些因素可能導致實際結果、活動水平、業績、成就和發展與這些前瞻性陳述所表達或暗示的結果存在重大差異。我們向美國證券交易委員會提交的文件中標題爲 “風險因素” 的章節描述了可能導致實際業績、發展和商業決策與前瞻性陳述存在重大差異的重要因素,包括我們最新的10-K表年度報告和10-Q表季度報告,包括但不限於我們業務固有的以下已知和未知的重大風險和不確定性:與我們成功商業化能力相關的風險產品,包括我們已獲得美國食品藥品監督管理局(“FDA”)批准的Amtagvi和Proleukin,我們已獲得美國食品藥品監督管理局和歐洲藥品管理局(“EMA”)的批准;EMA或其他前美國監管機構可能不批准或推遲批准我們提交的轉移性黑色素瘤lifileucel上市許可申請的風險;市場對我們產品的接受,包括Amtagvi和 Proleukin及其潛在定價和/或付款人報銷,如果獲得批准(對於我們的候選產品而言)美國和其他國際市場,以及這種接受度是否足以支持我們的產品(分別包括Amtagvi和Proleukin或候選產品)的持續商業化或開發;接受治療的患者數量和/或ATC是否是衡量商業成功和/或確認收入的適當衡量標準的風險;未來的競爭或其他市場因素可能會對Amtagvi或Proleukin的商業潛力產生不利影響;與我們使用療法制造能力或能力相關的風險第三方製造商或我們自己的工廠,包括我們在此類第三方製造商和我們自己的工廠提高製造能力的能力,可能會對我們的商業發佈產生不利影響;與使用不同製造工藝的合作者進行的臨床試驗結果可能不會反映在我們的贊助試驗中;成功整合最近收購的Proleukin的風險;成功開發或商業化我們的產品(包括Amtagvi和Proleukin)可能無法產生足夠收入的風險來自產品銷售,我們可能在短期內或根本無法盈利;與我們成功開發、提交、獲得或維持FDA、EMA或其他監管機構對候選產品的批准或其他行動的時機和能力相關的風險;我們的關鍵研究和隊列的臨床試驗結果以及與FDA、EMA或其他監管機構的會議是否可能支持註冊研究和後續批准 FDA、EMA或其他監管機構,包括計劃中的風險單臂 2 期 IOV-LUN-202 試驗可能不支持註冊;初步和中期臨床結果,可能包括正在進行的臨床試驗或隊列的療效和安全性結果,可能無法反映在我們正在進行的臨床試驗或這些試驗中的亞組的最終分析中,也可能無法反映在其他先前的試驗或隊列中;根據美國食品藥品管理局和其他監管機構的意見,可能需要根據我們的試驗和這些試驗中的隊列調整入組的風險;不斷變化的格局的風險對宮頸癌患者的護理可能會產生影響我們在該適應症中的臨床試驗;根據FDA、EMA或其他監管機構的反饋,我們可能被要求進行更多臨床試驗或修改正在進行或未來的臨床試驗的風險;我們對臨床試驗結果的解釋或與FDA、EMA或其他監管機構的溝通可能不同於此類監管機構對此類結果或溝通的解釋(包括我們先前與美國食品藥品管理局就我們的非小肺癌臨床會晤)的解釋試驗);來自Amtagvi正在進行的臨床試驗的臨床數據在正在進行或計劃中的臨床試驗中無法繼續或重複的風險,或者可能不支持監管部門的批准或續期授權的風險;意外支出可能減少我們估計的現金餘額和預測並增加我們的估計資本需求的風險;COVID-19 疫情的影響;以及其他不在我們控制範圍內的因素,包括總體經濟狀況和監管發展。

CONTACTS

聯繫人

Iovance Biotherapeutics, Inc:
Sara Pellegrino, IRC
Senior Vice President, Investor Relations & Corporate Communications
650-260-7120 ext. 264
Sara.Pellegrino@iovance.com

Iovance Biotherapeutics, Inc:
薩拉·佩萊格里諾,IRC
投資者關係與企業傳播高級副總裁
650-260-7120 分機 264
Sara.Pellegrino@iovance.com

Jen Saunders
Senior Director, Investor Relations & Corporate Communications
267-485-3119
Jen.Saunders@iovance.com

詹·桑德斯
投資者關係與企業傳播高級董事
267-485-3119
Jen.Saunders@iovance.com

Primary Logo

Source: Iovance Biotherapeutics, Inc.

來源:Iovance Biotherapeutics, Inc.

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論